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It is assumed that sheep and goats consumed the same bovine spongiform encephalopathy (BSE)-contaminated meat and bone
meal that was fed to cattle and precipitated the BSE epidemic in the United Kingdom that peakedmore than 20 years ago. De-
spite intensive surveillance for cases of BSE within the small ruminant populations of the United Kingdom and European Union,
no instances of BSE have been detected in sheep, and in only two instances has BSE been discovered in goats. If BSE is present
within the small ruminant populations, it may be at subclinical levels, may manifest as scrapie, or may be masked by coinfection
with scrapie. To determine whether BSE is potentially circulating at low levels within the European small ruminant populations,
highly sensitive assays that can specifically detect BSE, even within the presence of scrapie prion protein, are required. Here, we
present a novel assay based on the specific amplification of BSE PrPSc using the serial protein misfolding cyclic amplification as-
say (sPMCA), which specifically amplified small amounts of ovine and caprine BSE agent which had beenmixed into a range of
scrapie-positive brain homogenates. We detected the BSE prion protein within a large excess of classical, atypical, and CH1641
scrapie isolates. In a blind trial, this sPMCA-based assay specifically amplified BSE PrPSc within brain mixes with 100% specific-
ity and 97% sensitivity when BSE agent was diluted into scrapie-infected brain homogenates at 1% (vol/vol).
Transmissible spongiform encephalopathies (TSEs), or priondiseases, are a group of fatal neurodegenerative disorders that
affect a range of mammalian species, including important food
production animals and humans. The causal agent is proposed to
be an abnormal conformer of a host-encoded glycoprotein known
as PrPC (1), which is expressedmost highly in tissues of the central
nervous system (CNS). This abnormal (disease) conformer, PrPSc,
is responsible for the recruitment and conversion of PrPC to fur-
ther molecules of PrPSc. PrPSc has the propensity to form amyloid
fibrils, and its formation is thought to be linked to the neurode-
generation of tissues within the CNS. To date, PrPSc is the only
validated biomarker for these diseases. Examples of prion diseases
are Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep
and goats, and chronicwasting disease (CWD) in cervids. Another
priondisease, bovine spongiformencephalopathy (BSE), emerged
in the United Kingdom in the mid-1980s as a result of the recy-
cling of TSE-infected bovine slaughter offals via meat and bone
meal feed additives within the ruminant feed chain. In the mid-
1990s, incontrovertible biological and molecular evidence linked
the consumption of BSE-contaminated material to a new human
prion disease, variant CJD (2, 3), of which there have been 177
cases so far within the United Kingdom.
Sheep and goats are host to a number of prion strains, catego-
rized as classical, atypical (4), and CH1641-like scrapie (5); each
displays distinct PrPSc molecular phenotypes and pathologies.
Classical scrapie is likely to be made up of many distinct strains
(6). Distinguishing among the small ruminant prion strains is of
considerable interest due to the possible presence of BSE and the
recognition of a widespread novel prion strain, atypical scrapie,
within these species (7). Strain-typing methods that can distin-
guish classical scrapie isolates from experimental ovine BSE
and/or CH1641 isolates, including bioassays in inbred mice and
immunohistochemical analysis (8), have been reported. We and
others have reported rapid biochemical strain-typing tests involv-
ing the analysis of protease-resistant PrPSc. Such PrPSc types differ
between classical scrapie and BSE or CH1641 in terms of their
glycoform ratios and the sites of protease cleavage (9, 10). A more
difficult diagnostic challenge is the distinction of ovine BSE from
CH1641-like scrapie, as the two strains yield PrPScs that are indis-
tinguishable by conventional surveillance assays (11). However,
CH1641 and ovine BSE have been distinguished on the basis of a
higher resistance to denaturation shownbyovineBSE isolates (12)
or by multiplexed-antibody detection of protease-resistant PrPSc
fragments on Western blots (13). We also recently demonstrated
that ovine BSE isolates can be differentiated from classical, atypi-
cal, andCH1641 scrapie isolates by serial proteinmisfolding cyclic
amplification (sPMCA), a methodological approach that is
thought to replicate, in vitro, the prion conversion event associ-
atedwith these diseases and that can be used as a sensitive assay for
the detection of prions (14).
BSE prions are readily amplified under a set of defined condi-
tions in which all scrapie isolates tested were refractory to ampli-
fication irrespective of the PRNP genotype or scrapie strain (15).
Small ruminants, which are susceptible to experimental oral
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challenge by the BSE agent (16), were very likely fed BSE-contam-
inatedmeat and bonemeal before thismaterial was excluded from
ruminant feedstuffs. Despite intense surveillance to date, only two
instances of BSE (in goats) have been detected in small ruminants
(17, 18), and this very low incidence of BSE in small ruminants
remains unexplained. It is possible that BSE PrPSc is not detectable
by conventional PrPSc analysis either because it is present at very
low levels, its molecular phenotype has evolved during interspe-
cies transmission, and/or it is masked by scrapie during coinfec-
tions. Here, we report the development and application of a BSE-
specific sPMCA to an extensive range of BSE/scrapie agent mixes
which could be applied to the detection of BSE within TSE coin-
fections in small ruminants.
MATERIALS AND METHODS
TSE samples. All animal procedures were performed under Home Office
(United Kingdom) and local ethical review committee approval and in
compliance with the Animal (Scientific Procedures) Act 1986. Scrapie
samples (classical ovine and caprine, atypical ovine) from a wide geo-
graphical distribution in the United Kingdom and experimental ovine
and caprine BSE-infected brain material were provided by the AHVLA
biological archive. CH1641 samples from experimental challenges were
provided by Nora Hunter (The Roslin Institute). In total, 54 individual
scrapie isolates were used in combinations with 8 different BSE isolates. In
a blind trial, we analyzed a total of 216 TSE samples (108 BSE-scrapie
mixes and 108 scrapie-only samples) (Table 1). Samples were prepared as
10% (wt/vol) brain homogenates, as previously described (15).
sPMCA. sPMCA was carried out as previously described (15). Ten
percent (wt/vol) brain homogenate substrates were prepared from
scrapie-free sheep from a flock with extremely high levels of biosecurity
and no history of classical scrapie. After each sheep was euthanized, its
whole brain was immediately removed and kept on wet ice for up to 3 h to
allow transport back to the laboratory. Brain material was thoroughly
cleaned in 1 phosphate-buffered saline (PBS), and themeninges, visible
blood vessels, and signs of blood contamination were removed. Whole
brainswere then diced and flash frozen in liquid nitrogen before storage at
80°C. To prepare the sPMCA substrates, frozen brain material from
animals of either the AHQ/AHQ PRNP genotype (alanine, histidine, and
glutamine at codons 136, 151, and 170, respectively) or the VRQ/VRQ
PRNP genotype (valine, arginine, and glutamine at codons 136, 151, and
170, respectively) were defrosted on ice and then homogenized in a
blender at 10% (wt/vol) in ice-cold buffer consisting of 150 mM NaCl, 4
mM EDTA (pH 8.0), 1% (wt/vol) Triton X-100, and 1 protease inhib-
itor solution (Roche). The blended brain homogenate was then further
homogenized by bead beating for 30 s with 1-mm glass beads. After a
10-min centrifugation at 400  g, clarified 10% brain homogenate sub-
strate was aliquoted and stored at80°C until use.
Each sPMCA reactionwas set up by adding the test sample at a 1-in-10
dilution into AHQ/AHQ sPMCA brain homogenate substrate to a final
volume of 100 l. Samples were sealed within 0.2-ml PCR tubes and then
placed into an ultrasonicating water bath (model 4000; Misonix) at 37°C.
Sonications were performed for 40 s at 200W and repeated once every 30
min for 24 h (one sPMCA round), after which, the samples were diluted 1
in 3 with fresh substrate brain homogenate of the VRQ/VRQ genotype to
a final volume of 100l, and the samples were subjected to another round
of sPMCA. All samples were taken through a total of 5 rounds of sPMCA,
using AHQ/AHQ brain substrates at rounds 1, 3, and 5 and VRQ/VRQ
substrate at rounds 2 and 4.
Analysis of sPMCA products. Reaction products were digested with
proteinaseK (PK) and then analyzed byWestern blotting using themono-
clonal antibody SHa31 as described previously (15). Briefly, samples were
digested with 50g/ml PK in the presence of 0.045% (wt/vol) SDS for 1 h
at 37°C. Samples were boiled in 1 NuPAGE SDS-PAGE sample buffer
for 5 min, and then an equivalent to 2 l of the reaction products was
electrophoresed on 12% (wt/vol) polyacrylamide gels (precast NuPAGE
SDS-PAGE Bis-Tris; Invitrogen). Samples were transferred to polyvi-
nylidene difluoride (PVDF) membranes by electroblotting and then
blocked in 3% skimmedmilk-PBS. Blots were probed with SHa31mono-
clonal antibody ascites at a dilution of 1/80,000 (Cayman Chemicals) in
0.5% (wt/vol) skimmedmilk-PBS. After beingwashed, the blotswere then
probed using a secondary goat anti-mouse horseradish peroxidase (HRP)
conjugate at a 1/20,000 dilution (Dako). The blots were visualized using
an HRP chemiluminescent substrate (Geneflow) and a Photek imaging
system. Confirmatory analysis for the single-sample replicates was carried
out by the digestion of samples with PK followed by the detection of
prions by Western blotting using the antibodies P4 at a 1/2,000 dilution
(R-Biopharm) and SHa31 on two separate blots. Each blot was addition-
ally loaded with a 2-l sample of 10% brain homogenate from an ovine
scrapie isolate and an ovine BSE isolate to serve as blotting controls.
Analysis of BSE/scrapie agent mixes by Western blotting. BSE and
scrapie single-isolate samples were made up in proportions from 100%
BSE–0% scrapie agents in 10% increments to 0% BSE–100% scrapie
agents. We chose BSE and scrapie isolates that had approximately equal
amounts of PrPSc present as judged by Western blots of proteinase K-di-
gested brain material. These mixes were analyzed on replicate Western
blots using an anti-prion protein antibody, either P4 or SHa31. The blots
were evaluated by densitometry of the ratio of each glycan band thatmade
up the protease-resistant PrP triplet on the Western blots. Values for the
monoglycan-versus-diglycan signal for each sample lane were plotted to-
gether with additional BSE and scrapie isolates. The BSE/scrapie agent
mix samples were analyzed a total of three times for each mix on three
separate Western blots.
Densitometry and determination of SHa31/P4 ratio. For densitom-
etry, gel images were measured with ImageJ software. The lanes on the
TABLE 1 Scrapie isolates tested in mixes with BSE
Scrapie typea Genotypeb
No. of
isolatesc
No. of BSE
isolate
spikesd
No. of
analysese
Classical ARQ/ARQ 4 6 8
VRQ/VRQ 6 6 12
ARQ/VRQ 6 6 12
AHQ/AHQ 2 4 4
AHQ/ARQ 4 6 8
AHQ/VRQ 3 5 6
ARH/ARH 4 6 8
ARH/ARQ 4 6 8
ARH/VRQ 4 6 8
ARR/VRQ 4 6 8
Atypical AHQ/ARQ 4 6 8
ARR/ARR 1 2 2
ARQ/ARQ 1 2 2
CH1641 AHQ/ARQ 3 5 6
Caprine scrapie ARQ/ARQ 4 2 8
Total 54 108
a Scrapie isolates that were used in this study are listed as either classical, atypical, or
CH1641 (all ovine) or caprine scrapie.
b PRNP genotype of the scrapie isolate at codon positions 136, 154, and 171.
c The number of scrapie isolates of each individual genotype.
d The number of independent isolates of either ovine or caprine BSE that were spiked
into scrapie samples of that particular genotype. Each scrapie isolate was spiked with 2
distinct BSE samples. In total, 6 ovine BSE isolates were used (4 of the ARQ/ARQ
genotype, 2 of the AHQ/AHQ genotype), and 2 caprine BSE isolates were used (ARQ/
ARQ genotype).
e The number of individual sample mixes for each genotype that were prepared and
analyzed. Total number of BSE/scrapie mixes analyzed was 108; in addition, 108
samples consisting of just the scrapie samples alone were tested.
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Western blot were defined manually, and the lane pixel densities were
plotted, with the areas corresponding to the band peaks defined so that the
background for each lane could be subtracted. To remove subjectivity
when scoringweak signals after the initial SHa31Western blot analysis, we
imposed a threshold area value of 5,800 for samples to be deemed positive
in the first SHa31 screen. This threshold valuewas determined empirically
by looking at a number of negative-control sample lanes blotted and
probed in the same way as the samples under test. This figure represents
the mean plus 3 standard deviations (SDs) of the SHa31 Western blot
signal of 32 negative-control sPMCA samples.
The relative SHa31/P4 ratio, which is the ratio of the Western blot
signals produced by amplified sPMCAproducts when probedwith SHa31
and P4 monoclonal antibodies on two separate blots, is compared to the
SHa31/P4 ratio of a control scrapie sample analyzed on the same blots
(12). This relative ratio is a measure of the presence of the P4 epitope
within PrPSc, present at relatively high levels in ovine scrapie isolates, but
it occurs atmuch lower levels in ovine BSE isolates after PK digestion. The
absolute SHa31/P4 ratio was determined for each test sample. This abso-
lute ratio was then divided by the absolute ratio calculated for a scrapie
control that was probed on the same blots. This resulted in a relative
SHa31/P4 ratio for each sample. A cutoff value was derived by repeat
analysis of ovine BSE- and scrapie-infected samples, which allowed dis-
crimination between BSE- and scrapie-infected samples.
RESULTS
A standard methodology for the differentiation of BSE from
scrapie is the analysis of the PrPSc signals obtained from dual im-
munoblotting of samples with antibodies directed to the core and
toward the N terminus of the prion protein (9). After PK treat-
ment, BSE PrPSc generally lacks the epitope for themore N-termi-
nal antibody P4 but maintains reactivity to the core antibody.
Scrapie PrPSc is reactive to both antibodies. Here, dual immuno-
blotting differentiated samples of 100% BSE agent from those of
scrapie agent (Fig. 1A), but densitometry of these lanes to generate
an SHa31/P4 ratio suggested that this method distinguished only
the samples containing up to 80% BSE agent from scrapie agent
(data not presented). In addition to dual-antibody staining, mea-
surement of the glycoform ratios of the monoglycan and diglycan
PrPSc species can also be used to discriminate prion strains (19,
20). Densitometry of theWestern blot signals for the monoglycan
and diglycan PrPSc species within brain mixes provided data that
were plotted on a scatter plot, which demonstrated that isolates of
BSE and scrapie were clearly differentiated from each other (Fig.
1B). In this format, BSE-infected samples tended to cluster with a
greater proportion of diglycosylated PrP than did scrapie-infected
samples. Also plotted are themean ratios of BSE/scrapie agentmixes
(meanof 3 separate analyses). These data demonstrate the insensitiv-
ity of the current discriminatory assays and show that, at best, West-
ern blot analysis of brain samples can differentiate BSE/scrapie agent
mixes containing 60% BSE agent from natural scrapie isolates.
We previously detailed the selective in vitro amplification of
BSE PrPSc using specific brain substrates prepared from healthy
sheep (15). Here, this methodology was modified for the specific
amplification of BSE PrPSc within BSE/scrapie agent mixes, a sce-
nario which may mimic brain tissue within mixed prion infec-
tions. The sPMCA included a strategy that used ovine brain ho-
mogenate substrates from the AHQ/AHQ and VRQ/VRQ PRNP
genotype substrates, which were used in alternating sPMCA
rounds for a total of 5 rounds. This strategy puts greater selection
for the specific BSE PrPSc amplification over the amplification of
any scrapie prions present, as BSE PrPSc is amplified in both ge-
notypes and scrapie PrPSc amplification tends to be genotype re-
stricted. BSE-infected samples (3 isolates) were spiked into differ-
ent scrapie isolates and were detected at dilutions of 1/50, 1/125,
and 1/1,500, with 100%, 90%, and 80% sensitivities, respectively,
after 5 rounds of sPMCA (see Tables S1 and S2 in the supplemen-
tal material). A diverse set of scrapie-infected samples from awide
geographical distribution in the United Kingdom was collected,
including classical (ovine and caprine), atypical, and CH1641
scrapie isolates. BSE-infected samples came from experimentally
challenged sheep and goats (Table 1). Ten percent (wt/vol) BSE-
FIG1 Samples of BSE- and scrapie-infected brains were PKdigested,mixed in
different proportions (from 100% to 0% BSE agent in 10% increments as
indicated), and then Western blotted with an anti-prion antibody, either
SHa31 or P4. BSE agent was immunolabeled with SHa31 but not P4 (each
mixture ratio was prepared and analyzed 3 times on 3 separateWestern blots).
(A) Representative example of these blots. Lane M, molecular mass markers
(20 and 30 kDa). (B) The relative abundance of the monoglycan and diglycan
species within each of these mixed samples (SHa31 blot) was calculated by
densitometry. These values are plotted as a scatter plot using the mean values
of three analyses. BSE/scrapie agent mixes are plotted (black diamonds) and
labeled as the percentages of BSE agent content (vol/vol), with error bars de-
picting the plus or minus standard error of these means. Individual experi-
mental isolates of ovine BSE (gray squares) and isolates of classical ovine
scrapie (gray triangles) are plotted as a function of their monoglycan and
diglycan signals on an SHa31Western blot. Scrapie- and BSE-infected samples
clearly cluster on different sides of the plot, indicating the higher abundance of
diglycosylated PrP in PK-treated BSE-infected samples than in scrapie-in-
fected samples.
Detection of BSE in TSE Mixes
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and scrapie-infected brain homogenates were prepared (10). A
sample set consisting of 216 homogenates, 108 scrapie isolates
only and 108 scrapie and BSE isolates mixed at 1% (vol/vol), was
produced and then blinded by a third party. Samples (10l) were
amplified in duplicate by sPMCA for a total of 5 days. The samples
were digested with 50 g/ml proteinase K and thenWestern blot-
ted using the monoclonal antibody SHa31. Samples were scored
positive if at least 1 reaction gave a Western blot product that was
above the blotting mean background plus 3 SDs (Fig. 2A).
A single positive replicate from the amplified samples was re-
digested and probed with the antibodies SHa31 and P4 on sepa-
rate Western blots. Densitometric scanning of these blots deter-
mined a relative SHa31/P4 ratio. Sampleswith a relative SHa31/P4
ratio of 2.9 were defined as being of scrapie origin, and those
samples with a ratio of2.9were defined as containing BSE agent.
The value of 2.9 was derived from the densitometry analysis of 4
scrapie isolates run on 2 separate occasions and probed by SHa31
and P4. The mean SHa31/P4 ratio was 1.1, and the standard devi-
ation in these analyses was 0.6. A threshold value was taken as this
mean value plus 3 standard deviations, and this value (2.9) was
used as the cutoff, below which a sample was defined as being of
scrapie origin. The analysis of ovine BSE-infected brain samples
on 16 separate occasions (7 different brains) gave a mean
SHa31/P4 ratio of 4.5 (range, 2.9 to 7.9). In 9 of these analyses, the
P4 signal was below the blot threshold; therefore, a relative ratio
was not determined for these samples on these occasions. When
samples were positive by SHa31Western blotting but did not pro-
duce a measurable P4-reactive signal, they were regarded as being
BSE positive.
Across all of the amplifications, 32 negative-control sPMCA
samples were tested (substrate only); and they were all negative,
and 31 out of 32 positive controls (amplifying 0.1 l ovine BSE-
infected brain only) were positive. The blinded sample results are
summarized in Fig. 2 and 3; 108 of 108 scrapie-only samples were
negative for BSE, while 105 of 108 BSE-spiked scrapie-infected
samples produced a BSE-positive sPMCA product. BSE agent of
goat and sheep origin was amplified under these conditions. Of
the 3 BSE-spiked samples that did not amplify BSE PrPSc, 2 failed
to give an amplification product, and 1 amplified but had an
SHa31/P4 ratio indicative of scrapie.
DISCUSSION
It is possible that within TSE coinfections, the amount of BSE
agent that is present can be small and may vary in levels between
tissue types, which requires very sensitive assays for detection.
Strain-typing tests based onWestern blotmethodology are largely
applicable to pure strains only (9).Wedemonstrate here that these
methods, at best, differentiated a BSE/scrapie agent mix in a 60:40
proportion from isolates of scrapie. The detection of BSE agent
that may have lower levels than this, which may be present with
coinfection, requires assays that have far higher sensitivities. The
sPMCAmethodology described here has very high sensitivity and
specificity for BSE that can be used to differentiate the BSE prion
protein from classical, CH1641, and atypical scrapie prion pro-
tein, even when these different scrapie-infected brain materials
were present at a 100-fold excess over BSE-infectedmaterials. This
study was carried out using a comprehensive collection of scrapie
isolates within a range of PRNP genotypes. In a blind trial of 216
such samples, the BSE sPMCA test showed a specificity of 100%
(all 108 negative samples tested negative) and a sensitivity of
97.2% (105 of 108 positive samples tested positive). The positive
predictive value for the assaywas 100% (all 105 samples that tested
positive were true positives), and the negative predictive value was
97.3% (108 of the 111 samples that tested negative were true neg-
atives). The assay should prove extremely useful alongside current
screeningmethodology for the surveillance of small ruminants for
FIG 2 sPMCA amplification of BSE-infected brain homogenate spiked into a 100-fold excess of scrapie agent. (A) Representative Western blots from the blind
trial depicting duplicate sPMCA analyses of four separate BSE/scrapie agent mixes: lane 1, ovine BSE in ovine scrapie; lane 2, ovine BSE in atypical ovine scrapie;
lane 3, classical ovine scrapie only; and lane 4, atypical ovine scrapie only.S, PK-digested scrapie-infected brain blotting control; M, molecular mass markers
(20 and 30 kDa); NEG, 4 negative-control sPMCA amplifications that contained no TSE;BSE, positive-control amplifications that were spiked with 0.1 l of
10% ovine BSE-infected brain only. Blots were developed with SHa31 antibody. (B) Representative examples of putative BSE sPMCA-positive samples from the
blind trial probed with SHa31 (top) and P4 (bottom). Lanes 1, 3, 5, and 6, ovine BSE agent spiked into classical ovine scrapie; lanes 2 and 4, ovine BSE agent in
CH1641 scrapie; lanes 7 and 8, ovine BSE agent in atypical scrapie; and lane 9, caprine BSE agent in caprine scrapie.B, PK-digested BSE-infected brain blotting
control.
Gough et al.
3866 jcm.asm.org Journal of Clinical Microbiology
 o
n
 June 12, 2015 by Univ of Nottingham
http://jcm.asm.org/
D
ow
nloaded from
 
BSE, including the analysis of scrapie-positive samples for coin-
fectionwith BSE. This test can be applied to new or historical cases
of small ruminant TSE presenting with confusing pathology or
molecular phenotypes (17). The methodology could also be used
to inform assessments of risk to human health from animal prod-
ucts from experimentally mixed TSE infections.
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